Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$4.24 - $11.12 $1.51 Million - $3.95 Million
355,192 New
355,192 $2.02 Billion
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $3.58 Million - $8.65 Million
363,074 New
363,074 $3.66 Million
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $836,108 - $1.43 Million
39,739 Added 11.34%
390,269 $8.75 Million
Q2 2022

Aug 15, 2022

SELL
$17.78 - $42.39 $78,569 - $187,321
-4,419 Reduced 1.24%
350,530 $8.69 Million
Q1 2022

May 11, 2022

SELL
$29.67 - $60.28 $102,242 - $207,724
-3,446 Reduced 0.96%
354,949 $13.8 Million
Q4 2021

Feb 11, 2022

BUY
$47.84 - $64.34 $721,666 - $970,568
15,085 Added 4.39%
358,395 $21 Million
Q3 2021

Nov 12, 2021

BUY
$59.27 - $95.73 $938,955 - $1.52 Million
15,842 Added 4.84%
343,310 $20.3 Million
Q2 2021

Aug 11, 2021

BUY
$67.25 - $92.52 $1.56 Million - $2.14 Million
23,128 Added 7.6%
327,468 $28.4 Million
Q1 2021

May 13, 2021

SELL
$72.16 - $117.4 $785,317 - $1.28 Million
-10,883 Reduced 3.45%
304,340 $25.1 Million
Q4 2020

Feb 09, 2021

SELL
$38.09 - $100.95 $39,461 - $104,584
-1,036 Reduced 0.33%
315,223 $28.7 Million
Q3 2020

Nov 12, 2020

BUY
$30.41 - $40.5 $996,657 - $1.33 Million
32,774 Added 11.56%
316,259 $12.6 Million
Q2 2020

Aug 12, 2020

SELL
$20.21 - $35.23 $323 - $563
-16 Reduced 0.01%
283,485 $9.73 Million
Q1 2020

May 06, 2020

BUY
$17.28 - $31.88 $777,461 - $1.43 Million
44,992 Added 18.86%
283,501 $6.3 Million
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $267,706 - $414,454
19,993 Added 9.15%
238,509 $4.67 Million
Q3 2019

Nov 07, 2019

SELL
$15.47 - $22.5 $203,260 - $295,627
-13,139 Reduced 5.67%
218,516 $3.39 Million
Q2 2019

Aug 12, 2019

SELL
$15.61 - $20.44 $300,211 - $393,102
-19,232 Reduced 7.67%
231,655 $4.7 Million
Q1 2019

May 14, 2019

BUY
$13.15 - $18.71 $70,681 - $100,566
5,375 Added 2.19%
250,887 $4.41 Million
Q4 2018

Feb 11, 2019

SELL
$11.48 - $16.98 $244,099 - $361,045
-21,263 Reduced 7.97%
245,512 $3.15 Million
Q3 2018

Nov 09, 2018

SELL
$8.75 - $16.29 $207,847 - $386,952
-23,754 Reduced 8.18%
266,775 $0
Q2 2018

Aug 06, 2018

BUY
$9.16 - $13.48 $126,765 - $186,549
13,839 Added 5.0%
290,529 $3.29 Million
Q1 2018

May 15, 2018

BUY
$6.3 - $13.77 $782,466 - $1.71 Million
124,201 Added 81.45%
276,690 $2.7 Million
Q4 2017

Feb 09, 2018

BUY
$3.94 - $6.64 $600,806 - $1.01 Million
152,489
152,489 $931,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.